Centessa Pharmaceuticals — Investor Presentation (January 2024)
31 slides from Centessa Pharmaceuticals's investor presentation, Jan 9, 2024
Slide 1: January 2024 Corporate Overview
January 2024 Corporate Overview
Slide 2: Disclaimer
This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as adv
Slide 3: Our Mission: Discovering and developing medicines transformational for patients
Our Mission: Discovering and developing medicines that are transformational for patients 3 Multiple potential blockbuster assets Strong momentum entering 2024 with clinical milestones anticipated across our most advanced programs Strong balance sheet
Slide 4: Our Most Advanced Potential First-in-Class/Best-in-Class Medicines for Patients
4 Our Most Advanced Potential First-in-Class/Best-in-Class Medicines for Patients ASSET DISEASE MECHANISM PRE- CLINICAL PHASE 1 PHASE 2 REGISTRATIONAL SerpinPC Hemophilia B Activated Protein C Inhibitor ORX750 Narcolepsy Type 1 (NT1) and other sleep disorders Orexin Receptor-2 (OX2R) Agonist LB101 S
Slide 5: Executed and Delivered in 2023
5 Executed and Delivered in 2023 ACHIEVED MILESTONES Entered and closed 2023 with strong balance sheet Cleared IND for LB101 (PD-L1xCD47 LockBody) Initiated Phase 1/2a LB101 clinical trial Named ORX750 orexin agonist dev candidate Presented ORX750 preclinical profile at World Sleep Initiated dosing
Slide 6: 2024 Driving Momentum
6 2024 Driving Momentum ANTICIPATED MILESTONES LOCKBODY TECHNOLOGY PLATFORM LB101 Phase 1/2 study ongoing OREXIN AGONIST PROGRAM ORX750 Clinical POC data in healthy volunteers expected in 2024 HEMOPHILIA PROGRAM SerpinPC Registrational study interim analysis expected in 2024
Slide 7: Hemophilia Program
7 Hemophilia Program LockBody Technology Platform Orexin Agonist Program
Slide 8: Hemophilia B: Large Growing Market with Unmet Need
8 Hemophilia B: Large Growing Market with Unmet Need 1. Evaluate Pharma Analyst Consensus for 2023. 2. In Canada, a subcutaneous option is available for hemophilia B with inhibitors. A safe, subcutaneous and effective treatment has the potential to transform care for hemophilia B No subcutaneous tre
Slide 9: SerpinPC potential first-in-class subcutaneous therapy for hemophilia B
9 SerpinPC has the potential to be a first-in-class subcutaneous therapy with a differentiated safety profile for people with hemophilia B1 Novel mechanism of action Achieved 96% reduction in median all- bleeds ABR1 Shown to have a favorable safety profile; No thrombosis observed1 SerpinPC is an inv
Slide 10: SerpinPC: Novel Approach to Prevent and Reduce Bleeding
SerpinPC Designed to reduce levels of circulating activated protein C (APC) SerpinPC: Novel Approach to Prevent and Reduce Bleeding 10 Pr ot hr om bi na se
Slide 11: 96% Reduction in Median Annualized Bleeding Rate with SerpinPC in Phase 2a
96% Reduction in Median Annualized Bleeding Rate (ABR) Observed with SerpinPC in Phase 2a Study Efficacy Source: Phase 2a study data of SerpinPC from Part 5 (n=20). (Part 5: Blood (2023) 142 (Supplement 1): 2619. https://doi.org/10.1182/blood-2023-179969.) Part 5 dosing: 1.2 mpk of SerpinPC administ
Slide 12: SerpinPC Potential for Differentiated Safety Profile
SerpinPC Potential for Differentiated Safety ProfileSafety No observed thrombotic events or treatment- related sustained elevations of D-dimer to-date Source: Phase 2a study data of SerpinPC. Part 5: Blood (2023) 142 (Supplement 1): 2619. https://doi.org/10.1182/blood-2023-179969. Part 3-4: Blood (2
Slide 13: SerpinPC Ongoing Global Registrational Studies for Hemophilia B
SerpinPC Ongoing Global Registrational Studies for Hemophilia B Hemophilia B with inhibitors (n ≥ 12) Hemophilia B without inhibitors (n = 120) 77 SITES 20 COUNTRIESPrimary Endpoint: ABR at 24 weeks ABR is annualized bleeding rate. Primary endpoint is the rate of treated bleeds (expressed as ABR) in
Slide 14: Potential Multi-Billion Dollar Market Opportunities
14 Potential Multi-Billion Dollar Market Opportunities Hemophilia A Rare Bleeding Disorders (RBD) SerpinPC Hemophilia B without inhibitors Hemophilia B with inhibitors Hemophilia A and RBD REPRESENT SIGNIFICANT EXPANSION OPPORTUNITIES Evaluate Pharma Analyst Consensus for 2023.
Slide 15: Orexin Agonist Program
15 Hemophilia Program LockBody Technology Platform Orexin Agonist Program
Slide 16: Orexin agonists could transform standard of care for sleep-wake disorders
Orexin agonists have the potential to transform standard of care for individuals with sleep-wake disorders 16
Slide 17: ORX750 Mechanism of Action
ORX750 Highly potent, selective orexin receptor type 2 agonist Designed to restore orexinergic neurotransmission MOA 17
Slide 18: ORX750 a Potential Best-in-Class Oral OX2R Agonist
18 ORX750 a Potential Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders Preclinical data support potential expansion into broader sleep-wake disorders, including narcolepsy type 2 and idiopathic hypersomnia1 1. ORX750 preclinical data presentation at Worl
Slide 19: ORX750 Increased Wakefulness and Suppressed Cataplexy in NT1 Mice
Wakefulness Latency to Cataplexy Maximal effect Maximal effect ORX750 (mg/kg, p.o.) ORX750 Increased Wakefulness and Suppressed Cataplexy in NT1 Mice NT1 is Narcolepsy Type 1. % of Time Awake refers to time spent awake in the first 3 hours after oral dosing. ORX750 preclinical data presentation at W
Slide 20: Potential Multi-Billion Dollar Market Opportunities
20 Potential Multi-Billion Dollar Market Opportunities Narcolepsy Type 1 Narcolepsy Type 2 Idiopathic hypersomnia Excessive daytime sleepiness (EDS) in common disorders ORX750 & Follow Up Orexin Agonists Evaluate Pharma Analyst Consensus for 2023.
Slide 21: ORX750 Clinical POC data in healthy volunteers expected in 2024
ORX750 Clinical POC data in healthy volunteers expected in 2024 21
Slide 22: LockBody Technology Platform
22 Hemophilia Program LockBody Technology Platform Orexin Agonist Program
Slide 23: LockBody Technology Platform aims to redefine immuno-oncology treatment
23 LockBody Technology Platform aims to redefine immuno-oncology treatment Novel pharmacology combining tumor enrichment with activation of effector function Designed as single agent systemic treatment Potential wide therapeutic index1 LB101 is an investigational agent that has not been approved by
Slide 24: LockBody LB101 Locked Configuration MOA
Locked Configuration MOA LockBody LB101 Conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody 24
Slide 25: LockBody LB101 Unlocked Configuration MOA
Unlocked Configuration LockBody LB101 Conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody MOA 25
Slide 26: Significant Tumor Regression Observed In-Vivo with LB101
Significant Tumor Regression Observed In-Vivo with LB101Efficacy Source: In vivo- 5 mg/kg of atezolizumab is equivalent to 8.5 mg/kg of LB101. Data presented at ASCO in June 2022. https://investors.centessa.com/static-files/2f9bffb4-97a6-4320-8885- 70f12aa4d036. MC38 hPD-L1+ syngeneic model in mouse
Slide 27: Well Tolerated in Non-Human Primates with LB101 Doses up to 50mg/kg
Observed to be Well Tolerated in Non-Human Primates (NHPs) with LB101 Doses up to 50mg/kg Safety Source: In-vivo- LB101 delivered IV at 5, 20, 50mg/kg (q7d x 4) in non-human primates. No anemia/ thrombocytopenia No weight loss No change in red blood cell or hemoglobin 27
Slide 28: Dosing subjects in ongoing Phase 1/2a trial of LB101
Dosing subjects in ongoing Phase 1/2a first-in-human clinical trial of LB101 28
Slide 29: 2024 Driving Momentum
2024 Driving Momentum ANTICIPATED MILESTONES LOCKBODY TECHNOLOGY PLATFORM LB101 Phase 1/2 study ongoing OREXIN AGONIST PROGRAM ORX750 Clinical POC data in healthy volunteers expected in 2024 HEMOPHILIA PROGRAM SerpinPC Registrational study interim analysis expected in 2024 29
Slide 30: Our Mission: Discovering and developing medicines transformational for patients
Our Mission: Discovering and developing medicines that are transformational for patients Multiple potential blockbuster assets Strong momentum entering 2024 with clinical milestones anticipated across our most advanced programs Strong balance sheet 30
Slide 31: Centessa
>< CENTESSA
Centessa Pharmaceuticals — Investor Presentation (January 2024) on 6ix